Carmell Therapeutics Closes $4MM Series B Funding

Carmell Therapeutics closed a US $4MM Series B financing. Funds will support Phase III clinical development of Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product designed to treat bone fractures while reducing complications, infections and duration of care.

PBM technology allows for controlled release of growth...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us